We are a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Through our leading IFx technology, we are developing personalized innate immune agonist to overcome tumor resistance to immunotherapies like checkpoint inhibitors. We plan to initiate a Phase 3 Accelerated Approval trial for IFx-2.0 in an aggressive form of skin cancer called Merkel Cell Carcinoma in 2024 and to advance IFX-3.0, our 2nd innate immune agonist, for potential use in blood related cancers like aggressive lymphoma. Using our first-in-class Delta technology we are developing bi-specific immune modulating antibody drug conjugates (ADCs) targeting Myeloid Derived Suppressor Cells (MDSCs) to modulate their immunosuppressive effects on the tumor microenvironment. Our technologies are designed to overcome primary and acquired resistance to checkpoint inhibitors or cellular therapies in the treatment of cancer.